Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

TNBC cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (4) Antibiotic (1) Apoptosis (31) Aryl Hydrocarbon Receptor (1) Aurora Kinase (1) Autophagy (6) Bacterial (2) Bcl-2 Family (2) c-Myc (1) Casein Kinase (1) CD73 (1) CDK (6) DNA Methyltransferase (1) DNA/RNA Synthesis (3) Epigenetic Reader Domain (4) ERK (2) Eukaryotic Initiation Factor (eIF) (1) FAK (1) Ferroptosis (2) Glutaminase (3) HDAC (5) Histone Demethylase (3) Histone Methyltransferase (7) IAP (1) Influenza Virus (2) JAK (1) Ligands for E3 Ligase (1) MDM-2/p53 (4) mTOR (1) NF-κB (1) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (1) PAK (1) PARP (2) Phosphatase (3) PI3K (1) Potassium Channel (1) PROTACs (2) Protein Arginine Deiminase (1) Pyroptosis (1) Raf (1) Reactive Oxygen Species (3) SHP2 (1) Src (1) STAT (3) Survivin (1) TNF Receptor (1) TrxR (1) VD/VDR (1) VEGFR (1) VSV (2)
By Research Areas:	Cancer (72) Infection (3) Inflammation/Immunology (3)
Click Chemistry:	Alkynes (3)

Inhibitors & Agonists

Natural
Products

Click Chemistry

Targets Recommended: Nuclear Factor of activated T Cells (NFAT)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145143

anti-TNBC agent-1	Apoptosis	Cancer
anti-TNBC agent-1 is a potent anti-triple-negative breast cancer (TNBC) agent. anti-TNBC agent-1 exhibits potent activity against different breast cancer cells with IC₅₀ values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 induces apoptosis of SUM-159 cells through mitochondria pathway and causes G1 phase arrest of SUM-159 cells .

HY-133129

MS1943 1 Publications Verification	Histone Methyltransferase Apoptosis	Cancer
MS1943 is a first-in-class, orally bioavailable EZH2 selective degrader, with an IC₅₀ of 120 nM. MS1943 significantly reduces EZH2 protein levels in numerous triple-negative breast cancer (TNBC) and other cancer and noncancerous cell lines. MS1943 effectively blocks proliferation of multiple TNBC and other cancer cell lines .

HY-162575

Anticancer agent 231	ERK	Cancer
Anticancer agent 231 (Compound P5) is a tyrosine protein kinase inhibitor with a IC₅₀ value of 3.95 μM. Anticancer agent 231 inhibits the cell viability, cell proliferation, cell migration and cancer dryness of triple negative breast cancer (TNBC) cells by targeting EGFR-ERK 1/2 signaling pathway, and is expected to play an important role in the field of TNBC disease therapy .

HY-W338764

AHR agonist 3	Apoptosis Aryl Hydrocarbon Receptor	Cancer
AHR agonist 3 is an aryl hydrocarbon receptor (AhR) agonist, that can induces cell cycle arrest or apoptosis via activation of tumor-suppressive transcriptional programs. AHR agonist 3 inhibits triple-negative breast cancer (TNBC) stem cell growth via AhR while exhibits minimal cytotoxicity against normal human primary cells and can be used for cancer research .

HY-159613

PELP1-IN-1	Apoptosis	Cancer
PELP1-IN-1 is a PELP1 inhibitor. SMIP34 reduces cell viability and colony formation. PELP1-IN-1 induces apoptosis and cell cycle arrest at S phase. PELP1-IN-1 decreases the expression of PELP1. PELP1-IN-1 shows antitumor activity. SMIP34 has the potential for the research of triple-negative breast cancer (TNBC) .

HY-138071

8α-Tigloyloxyhirsutinolide 13-O-acetate 8αTGH	STAT Pyroptosis Apoptosis Reactive Oxygen Species c-Myc Bcl-2 Family TrxR	Cancer
8α-Tigloyloxyhirsutinolide 13-O-acetate (8αTGH) is a potent and orally active STAT3 inhibitor. 8α-Tigloyloxyhirsutinolide 13-O-acetate induces early oxidative stress and pyroptosis, and late DNA damage, cell cycle arrest, apoptosis in the TNBC cells. 8α-Tigloyloxyhirsutinolide 13-O-acetate suppresses tumor cell growth in vitro and tumor growth in vivo .

HY-157298

anti-TNBC agent-4	Apoptosis	Cancer
anti-TNBC agent-4 (compound 7) exhibits highly inhibitory activity against different TNBC cells with IC₅₀s from 0.37 μM to 1.52 μM. anti-TNBC agent-4 inhibits IKKβ mediated phosphorylation of IκB and p65. anti-TNBC agent-4 induces TNBC cells apoptosis .

HY-156077

anti-TNBC agent-2	Apoptosis DNA/RNA Synthesis	Cancer
anti-TNBC agent-2 (3j) an anti-Triple negative breast cancer (TNBC) purine derivative. anti-TNBC agent-2 induces MDA-MB-231 cells apoptosis, and inhibits its migration and angiogenesis. anti-TNBC agent-2 inhibits tumor growth and metastasis and reduces the expression of Ki67 and CD31 protein in TNBC xenograft models. anti-TNBC agent-2 can be used for Triple negative breast cancer (TNBC) research .

HY-155251

anti-TNBC agent-3	Apoptosis Bcl-2 Family	Cancer
anti-TNBC agent-3 (compound 3g) is an apoptosis inducer with anti-cancer cell proliferation activity. anti-TNBC agent-3 inhibits tumor growth and metastasis in triple-negative breast cancer (TNBC) xenograft models .

HY-168106

ZMF-24	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
ZMF-24 is an anti-triple-negative breast cancer (TNBC) agent with IC₅₀ values of 0.22 μM and 0.44 μM against TNBC proliferation in BT-549 cells and MDA-MB-231 cells, respectively. ZMF-24 inhibits Eukaryotic translation initiation factor 3 subunit D (EIF3D) that disrupts the energy supply of TNBC by inhibiting glycolysis and further induces profound TNBC apoptosis by stimulating persistent ER stress .

HY-155246

PARP1-IN-15	Apoptosis PARP	Cancer
PARP1-IN-15 (Compound 6) is a PARP1 inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .

HY-167854

KW-2450 free base	Others	Cancer
KW-2450 Free base is a potent multikinase inhibitor targeting Aurora A and B kinases, demonstrating significant antitumor activity against triple-negative breast cancer (TNBC). KW-2450 Free base effectively reduces cell viability, promotes apoptosis, and inhibits colony formation and mammosphere formation in TNBC cells. KW-2450 Free base significantly suppresses the growth of TNBC xenografts, leading to tetraploid accumulation followed by apoptosis or the survival of octaploid cells. KW-2450 Free base enhances the efficacy of combination therapy with the MEK inhibitor selumetinib, resulting in a synergistic antitumor effect in TNBC models. KW-2450 Free base also acts as an orally bioavailable inhibitor of IGF-1R and IR tyrosine kinases, contributing to its potential antineoplastic activity by inhibiting tumor cell proliferation and inducing apoptosis.

HY-163535

J208	HDAC DNA Methyltransferase Apoptosis	Inflammation/Immunology Cancer
J208 is a dual inhibitor for histone deacetylase (HDAC) and DNA methyltransferase (DNMT). J208 inhibits proliferation of cancer cells, as well as the migration/invasion of triple-negative breast cancer (TNBC) cells. J208 induces apoptosis, arrests the cell cycle at G0/G1 phase. J2008 activates the innate immune signalling pathway in TNBC, by inducing the expression of endogenous retroviruses (ERVs) .

HY-158049

Anticancer agent 199	Apoptosis Ferroptosis	Cancer
Anticancer agent 199 (Compound G-4) induces apoptosis in triple negative breast cancer (TNBC) cells via the mitochondrial pathway through inhibiting EGFR, AKT and MAPK pathways. Anticancer agent 199 also induces Ferroptosis by down-regulating LCN2. Anticancer agent 199 inhibits TNBC cell viability and migration, and induces S phase cell cycle arrest. Anticancer agent 199 is a derivate of cyclin-dependent kinase inhibitor Rocovitine .

HY-149398

PARP-1/2-IN-2	Apoptosis PARP CDK	Cancer
PARP-1/2-IN-2-IN-1 (Compound 12e) is a PARP1/2/CDK12 inhibitor (IC₅₀: 34, 30 and 285 nM respectively). PARP-1/2-IN-2 inhibits DNA damage repair, promotes cell cycle arrest and apoptosis. PARP-1/2-IN-2 inhibits the growth of TNBC cells and TNBC xenograft tumor .

HY-163381

Antiproliferative agent-48	Others	Cancer
Antiproliferative agent-48 (compound PC-A1) shows selective antiproliferative activity against triple-negative breast cancer (TNBC) cells .

HY-169212

I194496	Others	Cancer
I194496 is a potent cystathionine γ-lyase (CSE) inhibitor, with an IC₅₀ of 0.79 mM. I194496 can inhibit the growth of human TNBC cells via the dual targeting PI3K/Akt and Ras/Raf/ERK pathway and suppress the metastasis of human TNBC cells via down-regulating Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways .

HY-168043

STAT3-IN-35	STAT	Cancer
STAT3-IN-35 is a STAT3 inhibitor that binds to SH2 domain. STAT3-IN-35 inhibits the phosphorylation of STAT3 and possesses antiproliferative activities against triple-negative breast cancer (TNBC) cell lines. STAT3-IN-35 also has a toxicity and potent antitumor activity in a TNBC xenograft model .

HY-161831

Antitumor agent-175	Others	Cancer
Antitumor agent-175 (Compound Ru2) is an antitumor agent with photocytotoxicity, demonstrating selective antitumor effects against triple-negative breast cancer (TNBC) cells .

HY-101567

BMS-986158 2 Publications Verification	Epigenetic Reader Domain	Cancer
BMS-986158 is a potent BET inhibitor with IC₅₀s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively .

HY-158439

anti-TNBC agent-7	JAK STAT	Cancer
anti-TNBC agent-7 (Compound 13c) possesses anticancer activity, serving as a molecular probe to recognize and regulate the signal transduction of the USP21/JAK2/STAT3 axis, exhibiting nanomolar-level cytotoxicity against MDA-MB-231 and HCC-1806 cancer cells, effectively combating triple-negative breast cancer (TNBC) .

HY-149259

FAK-IN-9	FAK	Cancer
FAK-IN-9 (Compound 8f) is a potent and orally active FAK inhibitor with an IC₅₀ of 27.44 nM. FAK-IN-9 induces triple-negative breast cancer (TNBC) cell apoptosis .

HY-155490

Nur77 antagonist 1	Nuclear Hormone Receptor 4A/NR4A Apoptosis	Cancer
Nur77 antagonist 1(Compound ja) is a selective Nur77 antagonist(K_D ^SPR_Nur77 = 91 nM). Nur77 antagonist 1 induces cancer cell apoptosis. ja displays excellent antitumor against triple-negative breast cancer (TNBC) cells .

HY-162276

Anticancer agent 188	Reactive Oxygen Species DNA/RNA Synthesis	Cancer
Anticancer agent 188 (compound D43) inhibits DNA synthesis in TNBC cells, leading to cell cycle arrest at the G2/M phase. Anticancer agent 188 has anti-cancer viability by inducing ROS-mediated apoptosis and DNA damage .

HY-149847

JH530	Others	Cancer
JH530 is an effective methuosis inducer that inhibits the triple-negative breast cancer (TNBC) cells proliferation by causing intracellular complete vacuolization. JH530 has anti-tumor activity and can be used for cancer research .

HY-162752

Anticancer agent 250	Apoptosis	Cancer
Anticancer agent 250 (compound 104) has antitumor activity, inducing apoptosis, slowing proliferation, and degrading key oncogenic proteins (such as aRaf, CDK4 ) without inducing a heat shock response .

HY-163275

MDM2-IN-24	MDM-2/p53 Apoptosis	Cancer
MDM2-IN-24 (compound A3f) exhibits MDM2-inhibiting and MDMX-activating properties in triple-negative breast cancer (TNBC) cells, with apoptotic and anti-proliferative activities .

HY-16916

NS1643 1 Publications Verification	Potassium Channel Autophagy	Cancer
NS1643 is a partial agonist of human ether-a-go-go-related gene (hERG) K ⁺ channels with an EC₅₀ of 10.5 μM. NS1643 inhibits the growth of breast cancer tumors in TNBC mouse models. NS1643 inhibits cell migration and invasion of breast cancer cells .

HY-161601

Ferroptosis inducer-2	Ferroptosis Reactive Oxygen Species	Cancer
Ferroptosis inducer-2 (Compound 24) is an inducer for heme oxygenase-1 (HO-1). Ferroptosis inducer-2 exhibits anticancer activity against triple-negative breast cancer (TNBC) cells through induction of ferroptosis .

HY-156285

ZZM-1220	Histone Methyltransferase Apoptosis	Cancer
ZZM-1220 is a histone lysine methyltransferase G9a/GLP covalent inhibitor with IC₅₀s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase .

HY-122703

BETi-211	Epigenetic Reader Domain	Cancer
BETi-211 is an orally active BET inhibitor (K_i: <1 nM). BETi-211 inhibits growth of triple-negative breast cancers (TNBC) cell lines with IC₅₀ < 1 μM. BETi-211 degrades BET proteins and suppress tumor growth in xenograft breast tumors .

HY-161774

ST80	CD73	Cancer
ST80 is an inhibitor for interaction of OTUD4 and CD73. ST80 decreases CD73 protein level, increases CD73 protein turnover, reduces immune evasion of tumor cells, and thus exhibits antitumor efficacy against immunosuppressive triple-negative breast cancer (TNBC) .

HY-157210

CDK7-IN-26	CDK	Cancer
CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor (IC₅₀: 7.4 nM). CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC₅₀ of 0.15 μM .

HY-156296

CDK9-Cyclin T1 PPI-IN-1	CDK Apoptosis	Cancer
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC₅₀: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model .

HY-158378

Trivalent hydroxyarsinothricn R-AST-OH	Glutaminase	Cancer
Trivalent hydroxyarsinothricn (R-AST-OH) is a covalent and irreversible kidney-type glutaminase (KGA) inhibitor. Trivalent hydroxyarsinothricn binds to the glutamine binding site and forms a covalent bond with an active site cysteine residue. Trivalent hydroxyarsinothricn selectively kills triple-negative breast cancer (TNBC) cells and is not cytotoxic to the control cell line. KGA is the enzyme that controls glutamine metabolism and is correlated with tumor malignancy .

HY-164550

YF438	HDAC Ligands for E3 Ligase	Cancer
YF438 is an HDAC inhibitor with effective anticancer activity both in vitro and in vivo. YF438 inhibits the growth and metastasis of triple-negative breast cancer (TNBC) cells by blocking the interaction between HDAC and MDM2, inducing the dissociation of MDM2-MDMX, and promoting the degradation of MDM2 .

HY-N7225

Yuanhuacine Gnidilatidin	Others	Cancer
Yuanhuacine (Gnidilatidin), a diterpene from Daphne genkwa, is an effective and highly selective inhibitor of the basal-like 2 (BL2) subtype of TNBC. Yuanhuacine can induce G2/M cell cycle arrest and has broad anti-tumor activity. Yuanhuacine is an orally active DNA damaging agent .

HY-162250

MS8847	PROTACs Histone Methyltransferase	Cancer
MS8847 is a highly potent EZH2 PROTAC degrader that recruits the E3 ligase von Hippel-Lindau (VHL). MS8847 potently degrades EZH2 in a ubiquitin-proteasome system-dependent manner. MS8847 effectively inhibits the growth of acute myeloid leukemia (AML) and triple-negative breast cancer (TNBC) cells .

HY-129241

AGX51 5+ Cited Publications	Others	Cancer
AGX51 is a first-in-class pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist and degrader. AGX51 inhibits the Id1-E47 interaction, leading to ubiquitin-mediated degradation of Ids, cell growth arrest, and reduces viability. AGX51 inhibits the TNBC cell lines with IC₅₀s of nearly 25 μM. AGX51 can be used for the research of cancer .

HY-163805

UNC10245380	ERK TNF Receptor Akt	Cancer
UNC10245380 is a CIB1 inhibitor with an IC₅₀ value of 8 μM. Additionally, UNC10245380 inhibits the phosphorylation of AKT and ERK and upregulates the expression of TRAIL-R1/D5. UNC10245380 selectively induces cell death in CIB1-dependent cancer cells, highlighting its potential utility in the development of CIB1-targeted probes and cancer research .

HY-146452

Anticancer agent 57	Apoptosis	Cancer
Anticancer agent 57 (compound 14) potently inhibits MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC₅₀s of 6.43 ~ 8.00 μM. Anticancer agent 57 induces cell cycle arrest and significantly promotes apoptosis. Anticancer agent 57 inhibits tumor growth in nude mice xenografted with MADMB-231 cells. Anticancer agent 57 can be used for researching triple negative breast cancer (TNBC) .

HY-150609

SHP2/CDK4-IN-1	SHP2 Phosphatase CDK	Cancer
SHP2/CDK4-IN-1 (compound 10) is an orally active and potent SHP2 and CDK4 dual inhibitor, with IC₅₀ values of 4.3 and 18.2 nM, respectively. SHP2/CDK4-IN-1 effectively induces G0/G1 arrest to prevent the proliferation of TNBC cell lines. SHP2/CDK4-IN-1 shows significant antitumor efficacy in the EMT6 syngeneic mouse model. SHP2/CDK4-IN-1 can be used for triple-negative breast cancer (TNBC) research .

HY-N0331

Ziyuglycoside I	MDM-2/p53 Apoptosis	Cancer
Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics . Ziyuglycoside I triggers cell cycle arrest and apoptosis mediated by p53, it can be a potential agent candidate for treating triple-negative breast cancer (TNBC) .

HY-123870

MX107	Survivin IAP NF-κB	Inflammation/Immunology Cancer
MX107 is a selective and potent survivin inhibitor that suppresses triple-negative breast cancer (TNBC) cell proliferation. MX107 induces degradation of survivin and inhibitor-of-apoptosis proteins (IAPs), which inhibits nuclear factor κB (NF-κB) activation induced by DNA damage. MX107 enhances tumoricidal efficacy of genotoxic treatments synergized with chemotherapeutic drugs .

HY-123611

Supinoxin RX-5902	DNA/RNA Synthesis Apoptosis	Cancer
Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase (P-p68) and a potent first-in-class anti-cancer agent. Supinoxin interacts with Y593 phosphorylated-p68 and attenuates the nuclear shuttling of β-catenin. Supinoxin induces cell apoptosis and inhibits growth of TNBC cancer cell lines with IC₅₀s ranging from 10 nM to 20 nM .

HY-149354

Aurora Kinases-IN-4	Aurora Kinase	Cancer
Aurora Kinases-IN-4 (Compound 11c) is a covalent and ATP competitive aurora kinase A inhibitor (IC₅₀: 1.7 nM). Aurora Kinases-IN-4 inhibits cell proliferation in SJSA-1, MDA-MB-231, A54, HeLa cells with IC₅₀s of 4.27, 1.54, 3.08, 6.99 μM. Aurora Kinases-IN-4 can be used for research of triple negative breast cancer (TNBC) .

HY-130250

SR-4835 10+ Cited Publications	CDK Apoptosis	Cancer
SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC₅₀=99 nM, K_d=98 nM; CDK13: K_d=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death .

HY-144638

JMX0293	Apoptosis	Cancer
JMX0293 is an O-alkylamino-tethered salicylamide derivative compound. JMX0293 maintains good potency against MDA-MB-231 cell line (IC₅₀ = 3.38 μM) while exhibiting very low toxicity against human non-tumorigenic breast epithelial cell line MCF-10A (IC₅₀> 60 μM). JMX0293 inhibits STAT3 phosphorylation and contribute to apoptosis in TNBC MDA-MB-231 cells. JMX0293 significantly suppresses MDA-MB-231 xenograft tumor growth in vivo without significant toxicity .

HY-155179

ZMF-23	PAK HDAC	Cancer
ZMF-23 is a PAK1/HDAC6 dual inhibitor. ZMF-23 inhibits PAK1 and HDAC6 regulated aerobic glycolysis and migration. ZMF-23 induces TNF-α-regulated necroptosis, and further enhances apoptosis. ZMF-23 inhibits the Warburg effect and cell migration. ZMF-23 can be used for research of triple-negative breast cancer (TNBC) .

HY-15273

UNC0638 5+ Cited Publications	VSV Histone Methyltransferase Autophagy Influenza Virus	Infection Cancer
UNC0638 selectively inhibits G9a and GLP histone methyltransferases with IC₅₀ of 15 nM and 19 nM, respectively. UNC0638 inhibits TNBC cell invasion and migration in vitro. UNC0638 is also an inhibitor of EHMT1/2 and induces fetal hemoglobin (HbF) expression in human erythroid progenitor cell culture. In addition, UNC0638 has anti-FMDV (foot-and-mouth disease virus) and anti-VSV (vesicular stomatitis virus) activities, with excellent potency and selectivity against multiple epigenetic and non-epigenetic targets .

Cat. No.	Product Name		Classification

HY-135699

TD52 1 Publications Verification		Alkynes
TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity . TD52 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135699A

TD52 dihydrochloride 1 Publications Verification		Alkynes
TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity . TD52 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157411

anti-TNBC agent-5		Alkynes
anti-TNBC agent-5 (compound 10C) is a triple-negative breast cancer (TNBC) inhibitor with good stability and pharmacokinetic properties. anti-TNBC agent-5 exhibits antiproliferative activity against a variety of cancer cells. anti-TNBC agent-5 can also effectively inhibit TNBC lung metastasis activity in the MDA-MB-231 xenograft model. anti-TNBC agent-5 can be used in cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

TNBC cells

Inhibitors & Agonists

NaturalProducts

Click Chemistry

Natural
Products